Pulmonary hypertension in heart failure.

Area of Science:

• Cardiology
• Pulmonary Medicine
• Clinical Trials

Background:

• Pulmonary hypertension (PH) is common in heart failure (HF) and associated with poor prognosis.
• Accurate identification of PH in HF patients is crucial for optimizing treatment strategies.
• This review addresses the updated classification and therapeutic trials for PH in left heart disease.

Purpose of the Study:

• To inform about the revised classification of PH in left heart disease.
• To discuss current and upcoming clinical trials for PH treatment in HF.
• To provide an updated perspective on managing PH associated with HF.

Main Methods:

• Review of updated classification criteria for PH in left heart disease.
• Analysis of recent clinical trial data on PH treatments.
• Synthesis of current management guidelines for PH in HF.

Main Results:

• The classification of PH due to left heart disease now uses pulmonary vascular resistance to distinguish between isolated postcapillary and combined pre- and postcapillary PH.
• Recent clinical trials indicate that pulmonary vasodilators do not enhance outcomes in patients with PH due to HF.
• Current evidence does not support the use of PH-directed therapies for this patient group.

Conclusions:

• Management of the underlying heart disease and comorbidities remains the primary treatment approach for PH in HF.
• PH-directed therapies are not currently recommended for patients with PH due to HF.
• Further research may explore novel therapeutic strategies for PH in the context of HF.